For the quarter ending 2025-09-30, DRIO had $10,002K increase in cash & cash equivalents over the period. -$7,391K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -10,466 | -22,217 |
| Stock-based compensation | 2,950 | 4,377 |
| Depreciation and impairment | 73 | 174 |
| Change in operating lease right of use assets | -115 | -204 |
| Amortization of acquired intangible assets | 473 | 1,884 |
| Decrease in trade receivables, net | -181 | -2,248 |
| Increase in other accounts receivable, prepaid expense and long-term assets | 14 | -484 |
| Decrease (increase) in inventories | 260 | -143 |
| Increase (decrease) in trade payables | 90 | 334 |
| Decrease in other accounts payable and accrued expenses | -637 | -858 |
| Decrease in deferred revenues | 133 | -856 |
| Change in operating lease liabilities | -101 | -147 |
| Change in fair value of warrant liability | -78 | -825 |
| Non-cash financial expenses | 167 | 2,665 |
| Other | 4 | -654 |
| Net cash used in operating activities | -7,350 | -12,704 |
| Purchase of property and equipment | 41 | 75 |
| Net cash used in investing activities | -41 | -75 |
| Proceeds from issuance of common stock and prefunded warrants, net of issuance costs | 17,393 | - |
| Proceeds from issuance of preferred stock, net of issuance costs | 0 | 6,754 |
| Proceeds from borrowings on credit agreement, net | 0 | 31,700 |
| Repayment of long-term loan | 0 | 31,515 |
| Net cash provided by financing activities | 17,393 | 6,939 |
| Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents | 10,002 | -5,840 |
| Effect of exchange rate changes on cash | -19 | - |
| Cash and cash equivalents at beginning of period | 27,764 | - |
| Cash and cash equivalents at end of period | 31,907 | - |
DarioHealth Corp. (DRIO)
DarioHealth Corp. (DRIO)